Physician
Internal Medicine
Dr. Jerry Z. Yang, MD
|
|
Give Review
Jerry Yang practices Internal Medicine. He has 1 awards "Meaningful Use Stage 1 Certification". Jerry Yang is a published physician as well. He has 14 publications published. The latest was: Fluorescent Analogue of Batimastat Enables Imaging of -Secretase in Living Cells.
Publications
- Dual responsive polymeric nanoparticles prepared by direct functionalization of polylactic acid-based polymers via graft-from ring opening metathesis polymerization.
- Fluorescent Analogue of Batimastat Enables Imaging of α-Secretase in Living Cells.
- Inhibition of the enhancement of infection of human immunodeficiency virus by semen-derived enhancer of virus infection using amyloid-targeting polymeric nanoparticles.
- C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
- Development of a Folate Receptor (FR)-Targeted Indenoisoquinoline Using a pH-Sensitive N-Ethoxybenzylimidazole (NEBI) Bifunctional Cross-Linker.
- Discovery and Characterization of Atropisomer PH-797804, a p38 MAP Kinase Inhibitor, as a Clinical Drug Candidate.
- Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.
- Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies.
- Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
- Quantitative analysis of a model opioid peptide and its cyclic prodrugs in rat plasma using high-performance liquid chromatography with fluorescence and tandem mass sp...
- In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
- Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier us...
- Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.
Schools
West China University Of Medical Sciences
Kaiser Hospital
Doctors Specialties
- Internal Medicine
Accepted Insurances
- Commercial Insurance Company
- Kaiser Permanente
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Worker's Compensation WC
Awards
- Meaningful Use Stage 1 Certification
Education
-
Kaiser Permanente Medical Group -
West China University of Medical Sciences
Helpful Reviews
Similar Doctors
|
|
Dr. Nusrat I. Chaudhry, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenton L. Chung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian J. O'Neill, MD |
|
|
Dr. Irina A. Pyrkova-Corotan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter J. Peters, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie M. Nefkens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sonia Sutherland, MD
This Doctor is OpenDoctor Recommended.
|